A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019−2020

By W. Tan, Xiang Zhao, Xuejun Ma, Wenling Wang, P. Niu, Wenbo Xu, George F. Gao, Guizhen Wu. China CDC Weekly, 2020

688 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020 (2020, background): “Now named 2019-nCoV, the virus is distinct from both SARS-CoV and MERS-CoV, yet closely related (5,7).”
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 (2020, neutral): “SARS-CoV-2, a member of the Betacoronavirus genus, is closely related to severe acute respiratory syndrome coronavirus (SARS-CoV) and several bat coronaviruses (Lu et al., 2020; Tan et al., 2020; Zhou et al., 2020).”
Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 (2020, neutral): “4%) Interval, median days (interquartile range) Onset to admission 4 (2-6) 3.”
The immunology and immunopathology of COVID-19 (2022, background): “The first complete sequence of the novel beta coronavirus genome was then identified in January 2020 (1).”
Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions (2020, background): “On 29 December 2019, Chinese authorities identified a cluster of similar pneumonia cases of unknown aetiology in Wuhan City, Hubei Province, China (Tan et al. , 2020).”
Detection of SARS-CoV-2 in Different Types of Clinical Specimens. (2020, neutral): “(%) 14 (93) 6 (46) 75 (72) 5 (63) 126 (32) 44 (29) 3 (1) 0”